Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Influenza vaccine GSK2340272A · 1 trial · 1 indication
Titers are presented as geometric mean titers (GMTs). The flu strain assessed was Flu A/CAL/7/09. The reference seropositivity cut-off value was greater than or equal to (≥) 1:10.
| Arm | Type | Description |
|---|---|---|
| GSK2340272A GROUP | EXPERIMENTAL | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. |
| GSK2340274A GROUP | EXPERIMENTAL | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340274A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. |
| Name | Type | Description |
|---|---|---|
| Influenza vaccine GSK2340272A | BIOLOGICAL | Two intramuscular injections at Day 0 and Day 21 |
| Influenza vaccine GSK2340274A | BIOLOGICAL | Two intramuscular injections at Day 0 and Day 21 |
Inclusion Criteria: * Male or female aged 18 to 60 years inclusive, at the time of the first vaccination. * Subjects who the investigator believes that they can and will comply with the requirements of the protocol. * Written informed consent obtained from the subject. * Satisfactory baseline medic...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
Influenza vaccine GSK2340272A is an investigational vaccine developed by GSK plc for the prevention of influenza. It is a Phase 3 candidate that has been studied in a completed clinical trial evaluating immunological equivalence between two investigational influenza vaccines in adults.
Influenza vaccine GSK2340272A is being developed for the prevention of influenza, an infectious disease. The vaccine is intended for use in adults, as studied in a Phase 3 trial that enrolled 336 participants aged 18 years and older.
Influenza vaccine GSK2340272A is developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor of the clinical program for this investigational influenza vaccine.
Influenza vaccine GSK2340272A is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by the FDA. The Phase 3 trial for this vaccine has been completed.
Influenza vaccine GSK2340272A has been studied in one Phase 3 clinical trial, NCT00979407, titled "Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1)." The trial was completed, enrolled 336 participants, and was conducted in France and Germany.